Hemocromatosis: actualización clínica y diagnóstica
Resumen
La hemocromatosis es un desorden en el cual la sobrecarga progresiva de hierro puede llevar a complicaciones sistémicas con gran morbimortalidad. Es una entidad clinicopatológica, con múltiples genes comprometidos y una fisiopatología común, con una expresión clínica y fenotípica variable, que depende de múltiples factores, tanto individuales como ambientales. Para su diagnóstico y seguimiento adecuado es necesario tener en cuenta elementos clínicos, bioquímicos y moleculares. En esta revisión, se presentan las generalidades de la hemocromatosis, además de sus mecanismos fisiopatológicos y moleculares, teniendo en cuenta su valor para el diagnóstico de la enfermedad. Adicionalmente, se describe la clasificación y un algoritmo diagnóstico propuestos recientemente por grupos de trabajo de expertos, así como las opciones de manejo y seguimiento de los pacientes con hemocromatosis.
Descargas
Referencias bibliográficas
Barton JC, Edwards CQ, Acton RT. HFE gene: Structure, function, mutations, and associated iron abnormalities. Gene 2015;574:179-192. https://doi.org/10.1016/j.gene.2015.10.009.
von Recklinghausen F. Über Hämochromatose, in Heidelberg. Versammlung deutscher Naturforscher und Äerzte 1889:324–325.
Sheldon JH. Haemochromatosis. London: Humphrey Milford, Oxford University Press; 1935. https://wellcomecollection.org/works/zj47rzqy.
Edwards CQ, Griffen LM, Goldgar D, Drummond C, Skolnick MH, Kushner JP. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988;318:1355-1362. https://doi.org/10.1056/nejm198805263182103.
Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408. https://doi.org/10.1038/ng0896-399.
Anderson GJ, Bardou-Jacquet E. Revisiting hemochromatosis: genetic vs. phenotypic manifestations. Ann Transl Med 2021;9:731. https://doi.org/10.21037/atm-20-5512.
Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:328-343. https://doi.org/10.1002/hep.24330.
Pietrangelo A. Hereditary hemochromatosis. Biochim Biophys Acta 2006;1763:700-710. https://doi.org/10.1016/j.bbamcr.2006.05.013.
Girelli D, Busti F, Brissot P, Cabantchik I, Muckenthaler MU, Porto G. Hemochromatosis classification: update and recommendations by the BIOIRON Society. Blood 2022;139:3018-3029. https://doi.org/10.1182/blood.2021011338.
Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008;358:221-230. https://doi.org/10.1056/NEJMoa073286.
Crownover BK, Covey CJ. Hereditary hemochromatosis. Am Fam Physician 2013;87:183-190.
Salgia RJ, Brown K. Diagnosis and management of hereditary hemochromatosis. Clin Liver Dis 2015;19:187-198. https://doi.org/10.1016/j.cld.2014.09.011.
Brissot P, Pietrangelo A, Adams PC, de Graaff B, McLaren CE, Loréal O. Haemochromatosis. Nat Rev Dis Primers 2018;4:18016. https://doi.org/10.1038/nrdp.2018.16.
Kowdley KV, Brown KE, Ahn J, Sundaram V. ACG Clinical Guideline: Hereditary hemochromatosis. Am J Gastroenterol 2019;114:1202-1218. https://doi.org/10.14309/ajg.0000000000000315.
Pietrangelo A. Ferroportin disease: pathogenesis, diagnosis and treatment. Haematologica 2017;102:1972-1984. https://doi.org/10.3324/haematol.2017.170720.
Alexander J, Kowdley KV. Hereditary hemochromatosis: genetics, pathogenesis, and clinical management. Ann Hepatol 2005;4:240-247.
Swinkels DW, Janssen MC, Bergmans J, Marx JJ. Hereditary hemochromatosis: genetic complexity and new diagnostic approaches. Clin Chem 2006;52:950-968. https://doi.org/10.1373/clinchem.2006.068684.
Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol 2009;122:78-86. https://doi.org/10.1159/000243791.
Zanella I, Rossini A, Di Lorenzo D, Biasiotto G. Hereditary hemochromatosis: The same old song. Blood Cells Mol Dis 2015;55:216-217. https://doi.org/10.1016/j.bcmd.2015.06.015.
Leonard DG, Bagg A, Caliendo AM, Kaul KL, Deerlin VM. Molecular Pathology in Clinical Practice. NY, USA: Springer New York; 2007. ISBN 978-0-387-33227-7. https://doi.org/10.1007/978-0-387-33227-7.
Santos P, Krieger JE, Pereira AC. Molecular diagnostic and pathogenesis of hereditary hemochromatosis. Int J Mol Sci 2012;13:1497-1511. https://doi.org/10.3390/ijms13021497.
Porto G, Brissot P, Swinkels DW, Zoller H, Kamarainen O, Patton S, et al. EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH). Eur J Hum Genet 2016;24:479-495. https://doi.org/10.1038/ejhg.2015.128.
Zoller H, Schaefer B, Vanclooster A, Griffiths B, Bardou-Jacquet E, Corradini E, et al. EASL Clinical Practice Guidelines on haemochromatosis. J Hepatol 2022;77:479-502. https://doi.org/10.1016/j.jhep.2022.03.033.
Radio FC, Majore S, Aurizi C, Sorge F, Biolcati G, Bernabini S, et al. Hereditary hemochromatosis type 1 phenotype modifiers in Italian patients. The controversial role of variants in HAMP, BMP2, FTL and SLC40A1 genes. Blood Cells Mol Dis 2015;55:71-75. https://doi.org/10.1016/j.bcmd.2015.04.001.
Rossi E, Olynyk JK, Jeffrey GP. Clinical penetrance of C282Y homozygous HFE hemochromatosis. Expert Rev Hematol 2008;1:205-216. https://doi.org/10.1586/17474086.1.2.205.
Sandnes M, Ulvik RJ, Vorland M, Reikvam H. Hyperferritinemia-A clinical overview. J Clin Med 2021;10:2008. https://doi.org/10.3390/jcm10092008.
Adams PC, Barton JC. A diagnostic approach to hyperferritinemia with a non-elevated transferrin saturation. J Hepatol 2011;55:453-458. https://doi.org/10.1016/j.jhep.2011.02.010.
Legros L, Bardou-Jacquet E, Latournerie M, Guillygomarc'h A, Turlin B, Le Lan C, et al. Non-invasive assessment of liver fibrosis in C282Y homozygous HFE hemochromatosis. Liver Int 2015;35:1731-1738. https://doi.org/10.1111/liv.12762.
Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology 2010;139:393-408. https://doi.org/10.1053/j.gastro.2010.06.013.
Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211-218. https://doi.org/10.1016/s0140-6736(02)07447-0.
Dostalikova-Cimburova M, Balusikova K, Kratka K, Chmelikova J, Hejda V, Hnanicek J, et al. Role of duodenal iron transporters and hepcidin in patients with alcoholic liver disease. J Cell Mol Med 2014;18:1840-1850. https://doi.org/10.1111/jcmm.12310.
Girelli D, Pasino M, Goodnough JB, Nemeth E, Guido M, Castagna A, et al. Reduced serum hepcidin levels in patients with chronic hepatitis C. J Hepatol 2009;51:845-852. https://doi.org/10.1016/j.jhep.2009.06.027.
Pedersen P, Melsen GV, Milman N. Frequencies of the haemochromatosis gene (HFE) variants C282Y, H63D and S65C in 6,020 ethnic Danish men. Ann Hematol 2008;87:735-740. https://doi.org/10.1007/s00277-008-0506-8.
Arya N, Chakrabrati S, Hegele RA, Adams PC. HFE S65C variant is not associated with increased transferrin saturation in voluntary blood donors. Blood Cells Mol Dis 1999;25:354-357. https://doi.org/10.1006/bcmd.1999.0264.
Whitlock EP, Garlitz BA, Harris EL, Beil TL, Smith PR. Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2006;145:209-223. https://doi.org/10.7326/0003-4819-145-3-200608010-00009.
Grosse SD, Rogowski WH, Ross LF, Cornel MC, Dondorp WJ, Khoury MJ. Population screening for genetic disorders in the 21st century: evidence, economics, and ethics. Public Health Genomics 2010;13:106-115. https://doi.org/10.1159/000226594.
Wallace DF, Subramaniam VN. The global prevalence of HFE and non-HFE hemochromatosis estimated from analysis of next-generation sequencing data. Genet Med 2016;18:618-626. https://doi.org/10.1038/gim.2015.140.
Camaschella C, Roetto A, Calì A, De Gobbi M, Garozzo G, Carella M, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000;25:14-15. https://doi.org/10.1038/75534.
Rametta R, Dongiovanni P, Baselli GA, Pelusi S, Meroni M, Fracanzani AL, et al. Impact of natural neuromedin-B receptor variants on iron metabolism. Am J Hematol 2020;95:167-177. https://doi.org/10.1002/ajh.25679.
Beutler E. The HFE Cys282Tyr mutation as a necessary but not sufficient cause of clinical hereditary hemochromatosis. Blood 2003;101:3347-3350. https://doi.org/10.1182/blood-2002-06-1747.
Pietrangelo A. Hereditary hemochromatosis--a new look at an old disease. N Engl J Med 2004;350:2383-2397. https://doi.org/10.1056/NEJMra031573.
Burke W, Imperatore G, Reyes M. Iron deficiency and iron overload: effects of diet and genes. Proc Nutr Soc 2001;60:73-80. https://doi.org/10.1079/pns200069.
Barton JC, Barton JC. Autoimmune conditions in 235 hemochromatosis probands with HFE C282Y homozygosity and their first-degree relatives. J Immunol Res 2015;2015:453046. https://doi.org/10.1155/2015/453046.
Duan C, Wang M, Zhang Y, Wei X, Huang Y, Zhang H, et al. C282Y and H63D polymorphisms in hemochromatosis gene and risk of parkinson's disease: A meta-analysis. Am J Alzheimers Dis Other Demen 2016;31:201-207. https://doi.org/10.1177/1533317515602220.
Shen LL, Gu DY, Zhao TT, Tang CJ, Xu Y, Chen JF. Implicating the H63D polymorphism in the HFE gene in increased incidence of solid cancers: a meta-analysis. Genet Mol Res 2015;14:13735-13745. https://doi.org/10.4238/2015.October.28.36.
Zhang M, Xiong H, Fang L, Lu W, Wu X, Wang YQ, et al. Meta-analysis of the association between H63D and C282Y polymorphisms in HFE and cancer risk. Asian Pac J Cancer Prev 2015;16:4633-4639. https://doi.org/10.7314/apjcp.2015.16.11.4633.
Adams PC, Barton JC. How I treat hemochromatosis. Blood 2010;116:317-325. https://doi.org/10.1182/blood-2010-01-261875.
Prabhu A, Cargill T, Roberts N, Ryan JD. Systematic review of the clinical outcomes of iron reduction in hereditary hemochromatosis. Hepatology 2020;72:1469-1482. https://doi.org/10.1002/hep.31405.
Brissot P. Optimizing the diagnosis and the treatment of iron overload diseases. Expert Rev Gastroenterol Hepatol 2016;10:359-370. https://doi.org/10.1586/17474124.2016.1119043.
Rombout-Sestrienkova E, van Kraaij MG, Koek GH. How we manage patients with hereditary haemochromatosis. Br J Haematol 2016;175:759-770. https://doi.org/10.1111/bjh.14376.
Phatak P, Brissot P, Wurster M, Adams PC, Bonkovsky HL, Gross J, et al. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology 2010;52:1671-1779. https://doi.org/10.1002/hep.23879.
Vanclooster A, van Deursen C, Jaspers R, Cassiman D, Koek G. Proton pump inhibitors decrease phlebotomy need in hfe hemochromatosis: Double-blind randomized placebo-controlled trial. Gastroenterology 2017;153:678-680.e672. https://doi.org/10.1053/j.gastro.2017.06.006.
Moretti D, van Doorn GM, Swinkels DW, Melse-Boonstra A. Relevance of dietary iron intake and bioavailability in the management of HFE hemochromatosis: a systematic review. Am J Clin Nutr 2013;98:468-479. https://doi.org/10.3945/ajcn.112.048264.
Hagström H. Alcohol consumption in concomitant liver disease: How much is too much? Curr Hepatol Rep 2017;16:152-157. https://doi.org/10.1007/s11901-017-0343-0.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
